Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cancer therapy using tumor-associated antigens to reduce side effects.

Literature DB >> 19408102

Cancer therapy using tumor-associated antigens to reduce side effects.

Abstract

Tumor-associated antigens recently have become very popular in cancer therapy. They can be targeted to reduce side effects of traditional cancer therapy. In this review, ten promising tumor-associated antigens are being discussed in detail. The characteristics of each one are being reviewed in detail. Monoclonal antibodies attached to traditional anticancer agents can target a specific type of cancer cells thereby reducing the amount of traditional anticancer agents reaching normal tissues. This sort of cancer targeting can be a very attractive anticancer therapy because it substantially reduces the amount of side effects normally caused by traditional anticancer agents.

Entities: Chemical

Mesh：

Substances：

Year: 2009 PMID： 19408102 DOI： 10.1007/s10238-009-0047-z

Source DB: PubMed Journal: Clin Exp Med ISSN： 1591-8890 Impact factor: 5.057

119 in total

1. MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer.

Authors: M Hartman; A Baruch; I Ron; Y Aderet; M Yoeli; O Sagi-Assif; S Greenstein; Y Stadler; M Weiss; E Harness; M Yaakubovits; I Keydar; N I Smorodinsky; D H Wreschner
Journal: Int J Cancer Date: 1999-07-19 Impact factor: 7.396

2. Anti-tumor activity of dendritic cells transfected with mRNA for receptor for hyaluronan-mediated motility is mediated by CD4+ T cells.

Authors: Mikiko Fukui; Koji Ueno; Yutaka Suehiro; Yuichiro Hamanaka; Kohzoh Imai; Yuji Hinoda
Journal: Cancer Immunol Immunother Date: 2005-07-15 Impact factor: 6.968

3. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.

Authors: J Dannull; P A Diener; L Prikler; G Fürstenberger; T Cerny; U Schmid; D K Ackermann; M Groettrup
Journal: Cancer Res Date: 2000-10-01 Impact factor: 12.701

4. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.

Authors: Jung Y Kang; Marisa Dolled-Filhart; Idris Tolgay Ocal; Baljit Singh; Chen-Yong Lin; Robert B Dickson; David L Rimm; Robert L Camp
Journal: Cancer Res Date: 2003-03-01 Impact factor: 12.701

Cancer therapy using tumor-associated antigens to reduce side effects.

1. MUC1 isoform specific monoclonal antibody 6E6/2 detects preferential expression of the novel MUC1/Y protein in breast and ovarian cancer.

2. Anti-tumor activity of dendritic cells transfected with mRNA for receptor for hyaluronan-mediated motility is mediated by CD4+ T cells.

3. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.

4. Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer.

5. [Prognostic importance of preoperative CEA in patients with colorectal cancer].

6. c-met overexpression in supraglottic laryngeal squamous cell carcinoma and its relation to lymph node metastases.

7. Expression of apoptosis-associated protein RCAS1 in macrophages of histiocytic necrotizing lymphadenitis.

8. Expression of RCAS1 in human gastric carcinoma: a potential mechanism of immune escape.

9. [Expression of EP-CAM, beta-catenin in the carcinogenesis of squamous cell carcinoma of uterine cervix].

10. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer.

Review 1. Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors.

Review 2. Nanoformulation of natural products for prevention and therapy of prostate cancer.

Review 3. Monoclonal antibodies in neuro-oncology: Getting past the blood-brain barrier.